Granules India Ltd., a growing pharmaceutical manufacturing company, announced today results for its fourth quarter and financial year ended 31st March, 2017.
Financial Highlights of FY17 (Consolidated):-
- Revenue: Rs. 1,435 Cr., an increase of 4% compared to Rs.1,383 Cr. in FY16
- EBITDA: Rs. 309 Cr., an increase of 10% compared to Rs. 282 Cr. in FY16
- Operating Margin improved by 116 basis points from FY16
- Net Profit: Rs.165 Cr., an increase of 34% compared to Rs. 123Cr. in FY16
- Net Profit Margin improved by 257 basis points from FY16
Q4 FY17 Q4 FY16
- Revenue: Rs. 362 Cr. Rs. 376 Cr.
- EBITDA: Rs. 79 Cr. Rs. 80 Cr.
- Net Profit: Rs. 46 Cr. Rs. 33 Cr.
The Company's Board of Directors has proposed a final dividend of 25 paise /share of face value of Rs. 1 each.
"It was an eventful year, where we made several strides to strengthen our core business as well as progressed further with our emerging business initiatives. The work on API expansion at Bonthapally and PFI expansions at Gagillapur are on schedule and will contribute positively to our top line in the current financial year. We also initiated the construction of state-of-the-art green field facility in Vizag, India for venturing into oncology and speciality business. Granules Ominchem JV completed first full year of operations with a net profit of Rs. 24.9 Cr. Granules Ominchem JV completed US FDA inspection for the facility and EIR is awaited. During the year we filed three ANDAs from Gagillapur facility, India and one from Virginia facility, USA. Post approvals we expect this will boost our product offerings both on OTC and Rx space. We are driving towards the future with confidence, passion and commitment to emerge stronger and better in the coming year" said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited.
About Granules India Ltd.
(BSE: 532482, NSE: GRANULES)
Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.
The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.
Caution Statement:
Certain statements made above may be 'forward looking statements' within the meaning of applicable laws and regulations.
Media Contact:
Sumanta Bajpayee
[email protected]
91-40-30663572
Granules India Ltd
